Innate Pharma (IPHA) Intangibles (2017 - 2024)
Innate Pharma's (IPHA) quarterly Intangibles came in at $128149.6 in Q2 2024, down 86.97% YoY from $983298.7 in Q3 2023, and down 71.37% on a QoQ basis from $447591.0 in Q4 2023.
Innate Pharma (IPHA) Intangibles (2017 - 2024) Analysis & Trends
Innate Pharma (IPHA) has 8 years of Intangibles data on file, last reported at $128149.6 in Q2 2024.
- Quarterly Intangibles fell 86.97% year-over-year to $128149.6 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $128149.6 (down 86.97% YoY) and the FY2023 annual result came in at $447591.0, down 71.81% from the prior year.
- Intangibles retreated to $128149.6 in Q2 2024, from $447591.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $95.2 billion in Q2 2020 to a low of $128149.6 in Q2 2024.
- A 5-year average of $10.6 billion and a median of $46.2 million in 2022 frame the typical range for Intangibles.
- The widest YoY moves for Intangibles: up 8.4% in 2021, down 99.94% in 2021.
- Tracing IPHA's Intangibles over 5 years: stood at $55.2 million in 2020, then dropped by 8.4% to $50.6 million in 2021, then slumped by 96.86% to $1.6 million in 2022, then sank by 71.81% to $447591.0 in 2023, then sank by 71.37% to $128149.6 in 2024.
- The last three Intangibles figures came in at $128149.6 (Q2 2024), $447591.0 (Q4 2023), and $983298.7 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | - |
| 10 | Innate Pharma | 199.79 Mn | 199.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 128,149.62 |
| Dec 31, 2023 | 447,591.00 |
| Jun 30, 2023 | 983,298.73 |
| Dec 31, 2022 | 1.59 Mn |
| Jun 30, 2022 | 46.16 Mn |
| Dec 31, 2021 | 50.55 Mn |
| Jun 30, 2021 | 54.42 Mn |
| Dec 31, 2020 | 55.19 Mn |
| Jun 30, 2020 | 95.22 Bn |
| Dec 31, 2019 | 107.33 Mn |
| Dec 31, 2018 | 96.48 Mn |
| Dec 31, 2017 | 54.39 Mn |